Newron Pharmaceuticals S.p.A. (NWPHF)

8.52 0.00 (0.00%) At close: 04:42PM EDT

Newron Pharmaceuticals S.p.A.

Via Antonio Meucci 3
Bresso, MI 20091
Italy
39 02 610 3461
https://www.newron.com

Sector(s): 
Industry: 
Full Time Employees: 22

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Stefan Weber	CEO & Executive Director	505.57k	N/A	1965
Mr. Roberto Galli	Chief Financial Officer	N/A	N/A	N/A
Mr. Filippo Moriggia	Vice President of Operations	N/A	N/A	N/A
Dr. Ravi Anand M.D., Ph.D.	Chief Medical Officer	1.17M	N/A	1957
Ms. Laura Faravelli	Vice President of Business Development	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.

Corporate Governance

Newron Pharmaceuticals S.p.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.